Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunochemotherapy for visceral leishmaniasis: combinatorial action of Miltefosine plus LBSapMPL vaccine improves adaptative Th1 immune response with control of splenic parasitism in experimental hamster model.
Carvalho LM, Gusmão MR, Costa AFP, de Brito RCF, Aguiar-Soares RDO, Cardoso JMO, Reis AB, Carneiro CM, Roatt BM. Carvalho LM, et al. Parasitology. 2022 Mar;149(3):371-379. doi: 10.1017/S0031182021001906. Epub 2021 Nov 2. Parasitology. 2022. PMID: 35264268 Free PMC article.
Heterologous vaccine therapy associated with half course of Miltefosine promote activation of the proinflammatory response with control of splenic parasitism in a hamster model of visceral leishmaniasis.
Carvalho LM, Ferreira FC, Gusmão MR, Costa AFP, de Brito RCF, Aguiar-Soares RDO, Reis AB, Cardoso JMO, Carneiro CM, Roatt BM. Carvalho LM, et al. Curr Res Immunol. 2021 Nov 5;2:194-201. doi: 10.1016/j.crimmu.2021.10.003. eCollection 2021. Curr Res Immunol. 2021. PMID: 35492387 Free PMC article.
Immunoprophylaxis using polypeptide chimera vaccines plus adjuvant system promote Th1 response controlling the spleen parasitism in hamster model of visceral leishmaniasis.
Gusmão MR, Ostolin TLVDP, Carvalho LM, Costa AFP, Moreira GJL, Cardoso JMO, Aguiar-Soares RDO, Reis AB, de Brito RCF, Roatt BM. Gusmão MR, et al. Among authors: carvalho lm. Vaccine. 2022 Sep 2;40(37):5494-5503. doi: 10.1016/j.vaccine.2022.08.005. Epub 2022 Aug 10. Vaccine. 2022. PMID: 35963820 Free article.
High-through identification of T cell-specific phage-exposed mimotopes using PBMCs from tegumentary leishmaniasis patients and their use as vaccine candidates against Leishmania amazonensis infection.
Carvalho GB, Costa LE, Lage DP, Ramos FF, Santos TTO, Ribeiro PAF, Dias DS, Salles BCS, Lima MP, Carvalho LM, Dias ACS, Alves PT, Franklin ML, Silva RAM, Duarte MC, Menezes-Souza D, Roatt BM, Chávez-Fumagalli MA, Goulart LR, Teixeira AL, Coelho EAF. Carvalho GB, et al. Among authors: carvalho lm. Parasitology. 2019 Mar;146(3):322-332. doi: 10.1017/S0031182018001403. Epub 2018 Sep 10. Parasitology. 2019. PMID: 30198459
Evaluation of the protective efficacy of a Leishmania protein associated with distinct adjuvants against visceral leishmaniasis and in vitro immunogenicity in human cells.
Ribeiro PAF, Dias DS, Lage DP, Mendonça DVC, Vale DL, Ramos FF, Carvalho LM, Carvalho AMRS, Steiner BT, Roque MC, Oliveira-da-Silva JA, Oliveira JS, Tavares GSV, Martins VT, Chávez-Fumagalli MA, Roatt BM, Moreira RLF, Menezes-Souza D, Duarte MC, Oliveira MC, Machado-de-Ávila RA, Teixeira AL, Coelho EAF. Ribeiro PAF, et al. Among authors: carvalho lm, carvalho amrs. Parasitol Res. 2020 Aug;119(8):2609-2622. doi: 10.1007/s00436-020-06752-x. Epub 2020 Jun 13. Parasitol Res. 2020. PMID: 32535734
Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary study.
Mendonça DVC, Tavares GSV, Pereira IAG, Oliveira-da-Silva JA, Ramos FF, Lage DP, Machado AS, Carvalho LM, Reis TAR, Carvalho AMRS, Ottoni FM, Ludolf F, Freitas CS, Martins VT, Chávez-Fumagalli MA, Duarte MC, Humbert MV, Roatt BM, Menezes-Souza D, Alves RJ, Coelho EAF. Mendonça DVC, et al. Among authors: carvalho lm, carvalho amrs. Exp Parasitol. 2022 Feb;233:108205. doi: 10.1016/j.exppara.2021.108205. Epub 2021 Dec 28. Exp Parasitol. 2022. PMID: 34968460
A Pluronic® F127-based polymeric micelle system containing an antileishmanial molecule is immunotherapeutic and effective in the treatment against Leishmania amazonensis infection.
Tavares GSV, Mendonça DVC, Miyazaki CK, Lage DP, Soyer TG, Carvalho LM, Ottoni FM, Dias DS, Ribeiro PAF, Antinarelli LMR, Ludolf F, Duarte MC, Coimbra ES, Chávez-Fumagalli MA, Roatt BM, Menezes-Souza D, Barichello JM, Alves RJ, Coelho EAF. Tavares GSV, et al. Among authors: carvalho lm. Parasitol Int. 2019 Feb;68(1):63-72. doi: 10.1016/j.parint.2018.10.005. Epub 2018 Oct 16. Parasitol Int. 2019. PMID: 30339837
340 results